Ionis Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IONS | ARWR | ALNY | 4591.T | BBIO | DNLI | |
|---|---|---|---|---|---|---|
| Market cap | 6.67B | 8.71B | 21.57B | 3.39B | 15.17B | 3.35B |
| P/E (TTM) | — | — | 8.1 | — | — | — |
| Forward P/E | -35.0 | -12.4 | 14.4 | -1.1 | -225.0 | -8.9 |
| Price/book | 15.1 | 18.7 | 6.0 | 1.2 | -5.9 | 3.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −45.88% | +47.68% | −63.21% | −29.21% | +18.15% | +30.62% |
| Today | −0.67% | +3.56% | +0.74% | −4.76% | +5.21% | +7.76% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All IONS news ›Reviewing Ionis Pharmaceuticals (NASDAQ:IONS) & Pluri (NASDAQ:PLUR)
Posted by Michael Walen on Nov 2nd, 2026 Pluri (NASDAQ:PLUR – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside
Ionis Pharmaceuticals, Inc. is a long-term buy as launches, royalties, & pipeline growth boost revenue prospects despite cash burn. Click for an IONS stock update. - Ionis Pharmaceuticals, Inc.’s independent launches should increasingly…
Ionis Pharmaceuticals (IONS) Slips 2.23% as Partner Roche Reports 43% Proteinuria Drop in Kidney Study
Shares of Ionis Pharmaceuticals (IONS) experienced a 2.23% decline during regular market hours, closing at $42.93 after losing $0.98. The drop occurred even as partner company Roche unveiled encouraging Phase 3 trial data for sefaxersen in…
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
Ionis Pharmaceuticals (IONS) was on investors’ radar on Thursday after the biotech firm received Orphan Drug Designation from the U.S. Food and Drug Administration for an experimental treatment targeting Dravet syndrome, a rare genetic…
Ionis Pharmaceuticals (NASDAQ:IONS) Raised to Outperform at BMO Capital Markets
Posted by Tristan Rich on Oct 22nd, 2026 Check Out Our Latest Stock Report on Ionis Pharmaceuticals Ionis Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing medicines using antisense technology. Its…
Citi Reaffirms Buy on Ionis Pharmaceuticals (IONS) Despite Recent Stock Declines
The GF Score™ is a composite measure that evaluates a company’s overall fundamental quality by aggregating financial strength, profitability, growth, valuation, and momentum factors. Ionis Pharmaceuticals holds a GF Score™ of 63 out of…
Lobbying Update: $150,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed
$150,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. IONS insiders have traded $IONS stock on the open market 29 times in the past 6 months. Of those trades, 2 have…
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose
Ionis Pharmaceuticals said on Friday it would price its newly approved therapy to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the injectable drug, making it the... Biotechnology & Medical Research Ionis…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
- gurufocus.com1
- marketscreener.com1
- moneycheck.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.